15 results about "Development drugs" patented technology

The invention discloses a chronic disease intervention safety detection system and method based on large model multi-agent cooperation, and relates to the technical field of natural language processing and multi-agent cooperation in the medical health field. A standardized interface and an adaptive cleaning algorithm are adopted to realize data desensitization, missing value filling and format unification, and a dynamically updated patient health portrait is constructed; complex tasks are decomposed based on a chain reasoning technology, special tools such as a drug interaction detection tool and a nutrition gap calculation engine are developed, and a clinical knowledge base is integrated for parallel analysis; suggestion conflicts are eliminated through a multi-agent debate mechanism, the priority is calculated in combination with a weight rule, manual auditing is triggered to process low-confidence disputes, and finally a structured health report containing medication adjustment, diet optimization and behavior intervention is generated. The limitation of a traditional method in data integration, cross-domain reasoning and conflict resolution is solved.

The application discloses a sensitized ferroptosis lipid nano regulator and a preparation method and application thereof, and belongs to the technical field of new adjuvants and new dosage forms of drug preparation combined treatment. The lipid nano regulator is co-assembled by a GPX4 inhibitor and a FASN inhibitor through intermolecular forces, and is modified with an oxidation-reduction sensitive PEG modifier, a molar ratio of the GPX4 inhibitor and the FASN inhibitor is 10:1-1:10, a mass ratio of the sum of the GPX4 inhibitor and the FASN inhibitor to the PEG modifier is 10:90-90:10, and the intermolecular forces include pi-pi stacking force, hydrophobic force and hydrogen bond. The co-assembled nano preparation provides a new strategy and more choices for the development of drug delivery, and meets the urgent needs of high-efficiency and diverse ferroptosis treatment strategies in preparations in the clinic.

The invention discloses an antibody for specifically recognizing 1147th acetylation of ribosome biosynthetic factor 1 protein as well as a preparation method and application of the antibody. According to the protein sequence and the modification type of the ribosome biosynthetic factor 1, two modified antigen polypeptides A and B are designed, and through detection, the antibody obtained by immunizing animals with the two polypeptides has high specificity and affinity, can accurately recognize the acetylation modification form of the 1147th site of BMS1, and avoids recognition of an unmodified form or other modification sites. The antibody is suitable for various immunological detection methods, is high in repeatability and low in background, has mass production potential, can realize industrialization, not only can be used for evaluating the cis-platinum drug resistance condition in esophageal cancer treatment, but also can be used for various scenes such as basic research, disease mechanism analysis, biomarker development and drug target screening, and is wide in application range.

The invention provides application of Alda-1 in preparation of a preparation for improving a cognitive function, and belongs to the technical field of biological medicines. According to the method, the improvement effect of Alda-1 on cognitive competence is evaluated from the perspectives of working memory, suppression control, visual discrimination and the like, and results show that Alda-1 can improve the working memory ability, the suppression control ability and the visual discrimination ability. Therefore, the invention provides a safe and effective solution for developing new application of the Alda-1 medicine, guaranteeing the visual cognition ability of special occupational people and treating early neurological and mental diseases accompanied by visual cognition impairment.

The present invention relates to a non-human mammal model of HSV latent infection, which enables detection of HSV in mucosal tissue upon exposure to a stimulus that reactivates latent HSV within the body. The non-human mammal according to the present invention can contribute to elucidating the mechanism of HSV latent infection and reactivation in humans and to developing drugs and the like for HSV.

The present application relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, comprising: lipids and a targeting ligand; wherein the targeting ligand can specifically bind to a TREM2 receptor. The liposome of the present application can specifically bind to the TREM2 receptor by means of the targeting ligand, realize precise targeting of cells containing the TREM2 receptor on the surface, ensure direct action on target cells, and further improve the precision of delivered substances. The liposome has targeting property, high stability, small side effects, and can be applied to the development of drug carriers, pharmaceutical compositions, etc., and has a wide application prospect. For example, the liposome of the present application is dynamically connected with a hydrogel molecule by a borate ester bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome of the present application. The hydrogel pharmaceutical composition can release the liposome of the present application according to the change of pH and ROS in the surrounding environment in response to an inflammatory environment, and target cells containing the TREM2 receptor on the surface, i.e. microglial cells (having the TREM2 receptor on the surface), by virtue of the targeting ligand exposed on the surface, and regulate the polarization state of the cells, inhibit the polarization of the cells to the pro-inflammatory M1 type, and promote the polarization of the cells to the anti-inflammatory M2 type, thereby improving the local microenvironment of the spinal cord injury site and promoting nerve regeneration.

The application discloses an antibody capable of specifically recognizing acetylation of ribosome biogenesis factor 1 protein at the 1147th position, and a preparation method and application thereof. According to the protein sequence and modification type of ribosome biogenesis factor 1, two modified antigen polypeptides A and B are designed. It is detected that the antibody obtained by immunizing animals by using the two polypeptides has high specificity and affinity, and can accurately recognize the acetylation modification form of the 1147th position of BMS1, and avoid recognizing the unmodified form or other modification sites. The antibody is suitable for various immunological detection methods, has high repeatability, low background, has mass production potential, can be industrialized, and is not only used for evaluating the cisplatin resistance in esophageal cancer treatment, but also used for various scenes such as basic research, disease mechanism analysis, biomarker development, drug target screening, and has a wide application range.

One aspect of the invention provides a system for drug discovery, drug development, drug screening, or drug validation. The system includes: a sample chamber comprising a target protein and a drug candidate that may interfere with the target protein in the sample chamber, wherein the sample chamber is configured to: detect one or more of the following: (a) interference between the drug candidate the target protein and / or (b) one or more dynamics of the drug candidate on the target protein, wherein the one or more dynamics comprise affinity of the drug candidate to the target protein, and select the drug candidate if one or more desirable dynamics is detected. The system includes one or more immobilized surfaces and is configured to detect interactions between the drug candidate and the target protein at the single-molecule level.

The invention discloses a biological coupling method for polypeptide / protein main chain modification and synchronous fluorescence labeling, a conjugated receptor structure and application, and belongs to the technical field of polypeptide / protein coupling methods, chemically selective thiol coupling is achieved through conjugated receptors (CAs) derived from divinyl sulfide, the reaction process comprises amide activation and five-membered ring formation, and the conjugated receptors (CAs) are subjected to fluorescence labeling. Fluorescence labeling can be synchronously achieved, the fluorescence opening effect can be optically monitored in real time, and a built-in sensing mechanism is provided for dynamic reaction tracking. According to the invention, the technical problem that the polypeptide / protein main chain is difficult to modify due to factors such as poor stability, low biocompatibility, need of introducing an exogenous sequence and the like in the existing modification method is effectively solved, and a novel orthogonal technical platform is provided for protein engineering, biological conjugate development, drug design and biomolecular sensing; the method is suitable for the biomedical fields of biomarkers, fluorescence imaging, polypeptide / protein activity regulation and control and the like.

A method of detecting the presence of SARS-CoV-2 using oligonucleotide primer pairs is disclosed. Oligonucleotide primer pairs for the detection of SARS-CoV-2 using polymerase chain reaction (PCR)-based methods are also disclosed. Further, biomarkers and probes for SARS-CoV-2 detection are disclosed. The disclosure also relates to the identification and isolation of biomarkers for use as probes for the detection of SARS-CoV-2 and further use of the biomarkers as a target for the development of drug targets and therapeutics for SARS-CoV-2.

One aspect of the invention provides a system for drug discovery, drug development, drug screening, or drug validation. The system includes: a sample chamber comprising a target protein and a drug candidate that may interfere with the target protein in the sample chamber, wherein the sample chamber is configured to: detect one or more of the following: (a) interference between the drug candidate the target protein and / or (b) one or more dynamics of the drug candidate on the target protein, wherein the one or more dynamics comprise affinity of the drug candidate to the target protein, and select the drug candidate if one or more desirable dynamics is detected. The system includes one or more immobilized surfaces and is configured to detect interactions between the drug candidate and the target protein at the single-molecule level.

The invention provides philippine violet herb polysaccharide (VP-P) as well as a preparation method and application thereof. The VP-P is composed of glucose, galactose, xylose and arabinose, the molar ratio of glucose residues to galactose residues to xylose residues to arabinose residues is 6: 4: 1: 1, and the chemical structure of the VP-P comprises (1-> 6)-galactose residues, (1-> 4)-galactose residues, (1-> 4)-glucose residues, (1-> 4)-xylose residues and (1-> 4)-arabinose residues. The philippine violet herb polysaccharide (VP-P) prepared by the invention has remarkable anti-inflammatory activity, particularly has a remarkable effect in the aspect of treating pneumonia, and provides a new support for medicine development.

Provided are an ionizable lipid, a screening method therefor and application thereof. The molecular structure of the ionizable lipid can be predicted on the basis of a model algorithm, such that fundamental properties such as in-vivo mRNA delivery efficiency and apparent pKa can be predicted, and thus the present invention can be applied to formulation screening of mRNA lipid nanoparticles. Moreover, a physiologically-based pharmacokinetic (PBPK) model is developed for calculating a rate constant for a key step in the pharmacokinetics of lipid nanoparticles. The method and the model provide guidance for the research on and development of lipid nanoparticles, thereby facilitating the rapid development of mRNA-LNP drugs. By using a model simulation technique, a variety of new ionizable lipids, which can be used for an mRNA-LNP delivery system, can be obtained by means of screening, and the high delivery efficiency thereof has also been effectively verified.

The invention discloses application of bitter gourd-derived extracellular vesicle-like particles in preparation of medicines for resisting oxidation and delaying senescence. The bitter gourd extracellular vesicles provided by the invention have the effect of promoting cell activity after cell aging is induced by D-(+)-galactose so as to delay bEnd.3 cell aging, and can be used as an anti-aging raw material of cosmetics. An in-vivo experiment shows that the bitter gourd extracellular vesicles can improve rough hair of naturally aged rats, prolong the survival time of the rats, achieve the effects of resisting inflammation and oxidation and the like, and provide a new thought and basis for developing medicine aging-delaying health care products and cosmetics.

The present invention discloses a hybrid nanoassembly for dual-effect killing of tumor cells and tumor stem cells, and its preparation method and application, which belongs to the technical field of new excipients and new dosage forms for combined treatment of pharmaceutical preparations. The hybrid nanoassembly of the present invention is formed by co-assembly of a dimeric prodrug and a tumor stem cell inhibitor through intermolecular forces, and is surface-modified with a polyethylene glycol modifier. The preparation method of the hybrid nanoassembly of the present invention is simple and reliable, can achieve specific prodrug activation and on-demand drug release at the tumor site, has effective synergistic tumor killing and tumor stemness inhibition effects, and has high safety. The co-assembled nanoformulation of the present invention provides new strategies and more options for the development of drug delivery and multi-drug combination therapy, meeting the urgent clinical demand for new and efficient tumor cell / tumor stem cell dual-effect killing treatment strategies in formulations.